We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Reprogrammed Immune Cells Hunt Down and Destroy Cancer Cells

By HospiMedica International staff writers
Posted on 15 Aug 2023

The human body wards off illnesses by employing immune cells to enter and destroy disease cells. More...

However, certain dangerous cells, including some solid tumors, operate covertly, evading the body's regular immune system. Now, a breakthrough in targeted cell therapy makes it possible to reprogram a patient's own immune cells, giving them the ability to hunt down and destroy these cancer cells.

Edity Therapeutics (Rehovot, Israel) is reprogramming immune cells to serve as a delivery vehicle. These cells will contain therapeutic payloads, primed to locate and destroy not just cancer cells but also a range of diseases that currently lack a cure. The reprogramming immune cells, known as ED 007, will be trained by Edity to recognize solid tumors that generally elude recognition by the body's own immune system, enabling their unrestrained growth and metastasis. ED 007 will promote inflammation within these tumors, triggering the body's inherent immune response to destroy the cancerous cells. Given that the retrained cells are derived from the patient's own body, the risk of rejection and autotoxicity is likely to be minimal.

The concept of reprogramming a patient's own cells to fight cancer has demonstrated success in individuals with blood cancer. Edity is poised to take the next leap, aiming to utilize these retrained immune cells, including ED 007, to target solid tumors that create treatment challenges. Edity employs a straightforward yet potent process: Patients provide a blood sample from which specialized white blood cells known as T cells are extracted. These cells are then engineered in a laboratory setting to carry the necessary medication for treatment. After a brief incubation period, the engineered cells are reintroduced into the patient's body. Loaded with medication, the immune cells navigate directly to the patient’s damaged cells and start repairing the diseased tissues.

“Science allows us to treat any disease in a test tube but there are still many diseases with no cure,” Dr. Michal Golan-Mashiach, Edity’s CEO and Founder told The Times of Israel. “Edity’s technology will bring new treatment options to previously incurable diseases, offering new medicines to patients and their families.”

Related Links:
Edity Therapeutics 


Gold Member
12-Channel ECG
CM1200B
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Syringe Pump
SP50 Series
Patient Monitoring System
AlarmSense
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: A UTSW clinical trial studied a treatment strategy for kidney cancer with inferior vena cava tumor thrombus (IVC-TT) that used targeted radiation on the tumor thrombus followed by surgery to remove the kidney. (Photo courtesy of UT Southwestern)

Targeted Radiotherapy Before Surgery Improves Control of Kidney Cancer Thrombus

Inferior vena cava tumor thrombus occurs when kidney cancer extends into the body’s largest vein, potentially obstructing blood flow, progressing toward the heart, and making surgery more complex.... Read more

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Medical Imaging

view channel
Image: Brain PET imaging could help identify Alzheimer’s patients most likely to benefit from available therapies (Image Credit: iStock)

Amyloid and Tau PET Guide Selection and Monitoring of Alzheimer’s Therapy

Alzheimer’s disease is the most common form of dementia and can be difficult to distinguish from other causes of cognitive decline. According to the World Health Organization (WHO), 57 million people were... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: Steris is expanding its healthcare consumables portfolio through an agreement to acquire Xodus Medical, a surgical products business focused on patient and operating room staff safety.

Steris to Expand Surgical Safety Portfolio With $2.1 Billion Xodus Medical Deal

Steris has signed a definitive agreement to acquire Xodus Medical, a specialty surgical products business based in Pennsylvania, for $2.1 billion at closing. The acquisition will expand Steris’s healthcare... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.